Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"PD-L1 Immune checkpoint"”.
-
PROGRAMMED DEATH LIGAND 1 (PD-L1) IMMUNE CHECKPOINT-MEDIATED STIMULATION OF MALIGNANT PHENOTYPES IN TUMOUR CELLS
Most studies on the Programmed Death 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) immune checkpoint have focused on elucidating the signaling mechanisms leading to inactivation of immune effectors. We, along with others, have shown that signaling by the PD-1/PD-L1 immune checkpoint may be …
-
The Mechanism of cGAMP Induced Antitumor Effect and Its Application in Treating Cancer and Antibody Generation
… a notable target, primarily activates the innate immune system, inducing strong antitumor responses. Direct cGAMP delivery into tumors has demonstrated significant antitumor effects in vivo. Despite this, knowledge gaps persist regarding immune cell types in the tumor microenvironment and their …
-
Discovery of IKBKE and CD24 siRNAs for the treatment of triple-negative breast cancer
… aims to utilize a recently discovered anti-PD-L1 human domain antibody as an immune checkpoint inhibitor for cancer immunotherapy. In Chapter 1, we briefly introduced the background of the research, the statement of the problems, and research objectives. In Chapter 2, we reviewed potential …
-
Coordinated Blockade of TGF-β and PD-L1 Promotes Anti-Tumor Immunity in Ovarian Cancer Models
… diagnosis and high recurrence rates. Current immune checkpoint blockade (ICB) therapies show limited efficacy in HGSC, with no approved immunotherapy options for patients. This is due to an immunosuppressive tumor immune microenvironment (TIME) that limits the efficacy of ICB. Resistance to …
-
Exploring multivalency and chemical modifications in the development of anti-PD-L1 peptide inhibitors for cancer immunotherapy
The PD-1/PD-L1 immune checkpoint axis is one of the most common pathways exploited by cancers to evade immune surveillance. Many cancers overexpress PD-L1 (programmed cell death ligand 1) on their surface through which they interact with PD-1 (programmed cell death protein 1) on activated immune …